BioCorRx (BICX) Equity Average (2011 - 2026)

BioCorRx has disclosed Equity Average across 16 years of filings, most recently posting -$11.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at -$11.4 million, up 5.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.4 million (up 5.42% YoY), and the FY2025 annual result was -$11.8 million, down 5.7% from the prior year.
• Equity Average came in at -$11.4 million for Q1 2026 at BioCorRx, down from -$5.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$5.1 million in Q4 2025 to a low of -$12.2 million in Q4 2024.
• The 5-year median for Equity Average is -$9.0 million (2023), against an average of -$9.2 million.
• Across the five-year window, Equity Average tumbled 78.2% in 2022 and surged 58.32% in 2025, its largest moves.
• BioCorRx's Equity Average stood at -$7.7 million in 2022, then declined by 24.74% to -$9.6 million in 2023, then decreased by 26.78% to -$12.2 million in 2024, then soared by 58.32% to -$5.1 million in 2025, then tumbled by 125.03% to -$11.4 million in 2026.
• The last three Equity Average figures came in at -$11.4 million (Q1 2026), -$5.1 million (Q4 2025), and -$12.1 million (Q1 2025), per Business Quant data.